The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Vaping as a harm reduction measure in the lung screening population
Rachael Murray, PhD, University of Nottingham, Nottingham, UK, comments on the use and public health benefits of vaping products as an alternative to combustible tobacco. As vaping products are 95% less harmful than tobacco cigarettes, their use should be encouraged in the lung screening population as a harm reduction measure. However, that their use should not be normalized amongst non-smokers. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
